CHIKV |
U2OS |
Inhibiting viral RNA replication |
[75] |
CHIKV |
HEK 293T |
Blocking viral entry into target cells |
[74] |
CVB3 |
Vero |
Inhibiting viral RNA replication, improving the survival rate of infected cells |
[72] |
EBV |
B95.8 |
Down regulating RNA synthesis, inhibiting EBV lytic protein expression |
[31] |
HBV |
HepG2.2.15 |
Inhibiting HBs Ag and HBe Ag secretion |
[21] |
HBV |
HepG2.2.15 |
Opposing HBV-induced incomplete autophagy, reducing HBV replication |
[20] |
HBV |
HepG2.N10 |
Interfering core promoter transcription |
[19] |
HBV |
HepG2.117 |
Inhibiting RNA, DNA and cccDNA synthesis |
[23] |
HCV |
Huh7.5 |
Interfering virus adsorption, preventing cell-to-cell transmission |
[43] |
HCV |
Huh7.19 |
Inhibiting viral entry in to target cell |
[42] |
HIV |
MAGI |
Reducing Nf-kB expression and suppressing HIV-1 gene transcription |
[32] |
HIV |
peripheral blood lymphocytes |
Inhibiting viral replication |
[77] |
HIV |
HeLa-CD4-LTR-beta-gal |
Suppressing viral infection ability, inhibiting viral reverse transcription |
[38] |
HIV |
THP-1 |
Inhibiting viral transcription |
[78] |
HSV |
Vero, CV-1 |
In-activating viral |
[24] |
ZIKA |
Vero E6 |
Inhibiting viral entry in to target cell |
[73] |
H1N1 |
HEK 293T |
Destroying viral membrane integrity, preventing viral adsorption to cell surface |
[50] |
H1N1, |
MDCK |
Inhibiting erythrocyte agglutination and viral replication |
[51] |